

**“Therapeutic antibodies 2015: new trends in Oncology”**  
**(Institut Curie, 12 rue Lhomond, Amphitheater Constant Burg, Paris, November 13, 2015)**

8h15-8h45: Registration and coffee

8h45-9h00: Welcome address by **Dr. Geneviève Almouzni**, Director of Curie Institute Research Center and Opening Remarks by **Pr. H. Watier**, Head of the GDR CNRS #3260 “ACCITH” (“Antibodies and Therapeutic Targeting”)

**Keynote Lecture I:**

9h-9h40: **Dr. Janice Reichert** (Editor-in-Chief, *mAbs*; Managing Director, Reichert Biotechnology Consulting LLC, President, The Antibody Society) (Boston, USA)  
*“Antibodies to watch in 2016 in oncology”*

**1/ Antibody-drug conjugates in oncology: delivery tools for anti-tumor drugs**

9h40-10h: **Dr. Cécile Combeau** (Sanofi, Vitry-sur-Seine)  
*“Antibody-drug conjugate (ADC) clinical pipeline: a review”*

10h-10h20: **Dr. Laurent Ducry** (Lonza AG, Visp, Switzerland)  
*“Producing better ADCs using site-directed conjugation techniques”*

10h20-10h40: **Dr. Olivier Cochet** (Centre d’Immunologie Pierre Fabre, St Julien-en-Genevois)  
*“The evolving bioproduction landscape”*

10h40-11h10 Coffee break

**2/ Bispecific antibodies and Fc-optimized antibodies: less for better?**

11h10-11h30: **Dr. Claudine Vermot-Desroches** (iDD biotech, Lyon)  
*“Key features of novel Fc-engineered anti-CD19 MAbs with differential killing activity for B cell malignancies”*

11h30-11h50: **Dr. André Pèlerin** (IRCM, INSERM U.1194, Montpellier)  
*“From antibody combinations to bispecific antibodies and back: the quest for the best synergy between anti-tumor MAbs”*

11h50-12h10: **Dr. Alexandre Fontayne** (LFB Biotechnologies, Lille)  
*“Combined glyco- and protein-Fc engineering to enhance the cytotoxicity and half-life of therapeutic antibodies”*

12h10-12h30: **Dr. Stéphane Champiat** (INSERM U.981, Drug Development Department, Institut Gustave Roussy, Villejuif)  
*“The side effects and complications of antibody therapy”*

12h30-14h: **Lunch**

## **Keynote Lecture II:**

14h-14h40: **Pr. Michel Sadelain** (Memorial Sloan Kettering Cancer Center, New York, USA)  
*“T cell engineering: the CAR paradigm and beyond”*

### **3/ When fundamental immunology meets antibody: B cells within tumors and immune checkpoints**

14h40-15h: **Dr. Marie-Caroline Dieu-Nosjean** (Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris)  
*“Role of Tertiary Lymphoid Structure-associated B cells in anti-tumor immunity as antigen-presenting cells and tumor antigen-specific antibody-secreting cells”*

15h-15h20: **Dr. Christophe Caux** (INSERM U.1052, Cancer Research Center of Lyon (CRCL), and Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Centre Léon Bérard, Lyon)  
*“Importance of the ICOS/ICOSL in Regulatory T cell biology in breast cancer: a potential target for antibodies?”*

15h20-15h40: **Dr. Magali Terme** (Université Paris-Descartes, INSERM U.970, Paris)  
*“Control of the anti-tumor adaptive immune response by VEGF-A and its targeting by antibodies”*

15h40-16h10 Coffee break

### **4/ Antibodies in clinical oncology: the new wave**

16h10-16h30: **Dr. Thierry Wurch** (Institut de Recherches Servier, Croissy-sur-Seine)  
*“DART: discovery platform and clinical trials”*

16h30-16h50: **Dr. Jean Michon** (Department of Pædiatric Oncology, Institut Curie, Paris)  
*“Looking for an acceptable approach for the treatment of children with high-risk neuroblastoma by using an anti-GD2 chimeric 14.18 antibody”*

16h50-17h10 : **Pr. Catherine Thieblemont** (Lymphoma Unit, INSERM U.728, Hôpital Saint Louis, Paris)  
*“New trends in antibody-based therapy of lymphomas”*

17h10-17h15: Closing Remarks